Category Archives: Global

BIO 2014 Takeaway: The Peace Dividend

A surprising take away from the BIO International Convention in San Diego last month is the stark contrast between cooperative industry engagement and an unstable geopolitical order marked by xenophobia, drift and active, often violent government disengagement from the hard work of building common ground. While BIO held 29,000 partnering meetings over four days, convened […]
Also posted in Biotech, Emerging Markets, Europe, Events | Tagged , , | Leave a comment

Takeda's New Vaccines Division Charts Course to Global Growth

Today’s vaccines business represents an almost perfect world for big Pharma. There is a vast landscape of unmet medical need; lots of new science; longer product life cycles, with low exposure to post-patent generic competition; greater stability in pricing and supply commitments; more cost-effective manufacturing and delivery technologies; and the reputational gains that come from […]
Also posted in Strategy | Tagged , , | Leave a comment

EMA Delays Adoption of Policy on Publishing Trial Data

The European Medicines Agency (EMA) has postponed formal adoption of the policy on publication of clinical trial data. An EMA press statement said that “[f]urther clarifications on wording and practical arrangements will be discussed by Board members”, whose additional contributions will now be considered with a view to reaching final agreement at the Management Board meeting on 2 October. […]
Also posted in Europe, R&D, Regulatory | Tagged , | Leave a comment

Further Boost for Europe’s Largest Healthcare Partnership

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has announced the launch of IMI2, with a budget of €3.3 billion (US$ 4.5 bn). IMI (the Innovative Medicines Initiative) is a public-private partnership (PPP) between the European Commission and EFPIA, and was already the largest healthcare PPP in Europe. The budget for its first phase (2008-2013) […]
Also posted in Europe | Tagged , , , , , | Leave a comment

Industry Challenged: “Do More for Teenagers with Cancer”

By Leela Barham. Accessing the latest cancer drugs always seem to be controversial. Not just because of the money but also because of the complexities of accessing treatments during their development. This seems to be especially the case for young people with cancer, according to the UK’s Teenage Cancer Trust. 
Also posted in Europe, Guest Blog, R&D | Tagged , , , | Leave a comment
  • Categories

  • Meta